Immobilization of a ligand that selectively interacts with cancer cells to nanomaterials can enhance their diagnostic and therapeutic efficiency. In this study, we firstly demonstrate the high expression of receptor for cyclic nine-amino acid peptide LyP-1 (Cys-Gly-Asn-Lys-Arg-Thr-Arg-Gly-Cys) in both mouse and human pancreatic cancer. Based on these findings, sub-50 nm multifunctional superparamagnetic mesoporous nanospheres with surface modified with LyP-1 are rationally designed. Theses nanospheres have a core of silica-protected magnetite nanoparticle and a shell of FITC-labeled mesoporous silica, and they are able to specifically recognize and conjugate with the pancreatic cancer cell in vitro, as verified by the combined techniques of fluorescent imaging and T2 weight magnetic resonance imaging. After systematic administration, these LyP-1 immobilized nanospheres are found to actively target to mouse orthotopic xenograft of pancreatic cancer, which opens up the door for applications in early probing and diagnosis of pancreatic cancer by the multimodal imaging.
Introduction
Pancreatic cancer remains a major challenge to scientists and clinicians alike, and its mortality remains nearly identical to its incidence [1] . More than 80% of patients are not candidates for potentially curative resection because of local advanced disease or the presence of distant metastasis at time of diagnosis [2] , therefore, it is urgent to improve the early diagnosis in pancreatic cancer. Among various imaging options, magnetic resonance imaging (MRI) is a widely used tool for cancer diagnosis because of its noninvasiveness, lack of irradiation, high signal-to-noise ratio, high spatial resolution and ability to generate 3-dimensional images. Contrast agents are always administered during MR scans to acquire high-quality images by changing the response of nearby atoms of tissues in the external magnetic field [3e5]. However, the main MR contrast agents currently in clinic use, such as Gd-DTPA-BMA (Omniscan) and Gd-DTPA (Magnevist) suffer from low efficiency of relaxation and lack of tissue specificity. Therefore, development of new magnetic resonance imaging contrast agents has becomes a major research focus [6e12] .
Iron oxide nanomaterials, such as superparamagnetic magnetite nanoparticles, have recently emerged as important alternative MRI contrast agents for disease diagnosis, due to their biocompatibility [13] , good dispersibility and their ability to significantly shorten proton relaxation (T2 relaxation) and give a ''darker'' image of the targeted area. The conventional administrated iron oxide nanoparticles, which could accumulate in tumor tissue through enhanced permeability and retention effects (EPR), obviously lacks specificity [14e16] . To date, in order to enhance their targeting efficiency, iron oxide nanoparticles have been conjugated with specific ligands, such as vitamins [17, 18] , antibodies [10,19e21] , peptides [22, 23] , polysaccharides [24, 25] , nucleotides [26] , aptamers [27] and other synthetic mimetics, which can bind the molecules specifically expressed on tumor. However, in most previous reports, magnetic nanoparticles were usually used in the form of polymer-iron oxide nanocomposites with poorly defined morphology, structure and surface functionalities [28, 29] . Therefore, it is critical to design new multifunctional nanomaterials with well protected iron oxide, effectively immobilized targeting agent to achieve an effective, specific and multi-modal imaging for cancer diagnosis.
LyP-1 is a cyclic nine amino acid peptide (Cys-Gly-Asn-Lys-Arg-Thr-Arg-Gly-Cys) and screened from phage display peptide library. Several studies have shown that LyP-1 is an ideal candidate molecule for target diagnosis and therapy in breast cancer, hepatocarcinoma and atherosclerotic plaque [30e35] . Recently, the p32 or gC1qR receptor, a protein primarily localized in the mitochondria [36, 37] , has been confirmed to be a target molecule for the LyP-1peptide [38] .
In this study, for the first time, we reported the aberrant membrane expressions of p32 in C57BL/6 mouse derived pancreatic cancer cell line Pan02 and its corresponding orthotopic transplantation pancreatic cancer xenograft. Based on these findings, we designed novel multifunctional core-shell magnetic nanospheres by coating iron oxide nanoparticles with a layer of fluoresceinelabeled silica and subsequent covalently immobilizing the target LyP-1 for fluorescent and MRI imaging in mouse orthotopic pancreatic cancer. The multi-functional nanospheres were synthesized through a stepwise sol-gel coating process as shown in Fig. 1 . The obtained multifunctional nanospheres were demonstrated to be effective in conjugating with pancreatic cancer cell and cause a marked MRI signal reduction under T2 relaxometry in vitro. In vivo experiments showed these nanospheres ambiguously fluorescently labeled tumor tissue and detected orthotopic pancreatic cancer in C57BL/6 mouse as MR contrast agents.
Experimental section
2.1. p32 expression in pancreatic cancer tissues and cell lines
Cell line and cell culture
The murine pancreatic adenocarcinoma cell line Pan02 was purchased from the Frederick National Laboratory for Cancer Research (Maryland, USA) and maintained in RPMI 1640 (Gibco, California, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, California, USA) and 2 mM L-Glutamine. Murine endothelial cell lines (MS1) were obtained from Type Culture Collection Cell Bank of Chinese Academy of Sciences (Shanghai, China) and maintained in DMEM (Gibco, California, USA) supplemented with 10% FBS. All cell lines were maintained in humidified incubator at 37 C with 5% CO 2 .
Establishing orthotopic pancreatic cancer model in C57BL/6 mice
Syngeneic pancreatic cancer cell line Pan02 and Matrigel were used to establish orthotopic pancreatic cancer model in C57BL/6 mice as we described previously [39] . Briefly, 6e8-week old female C57BL/6 mice with body weight of 18e22 g (Shanghai Slac Laboratory Animal Co. Ltd., China) were anesthetized by intraperitoneal injection of 1% phenobarbital (70 mg/kg). After local shaving and disinfection, the abdominal cavity was opened by a 1.5-cm-long longitudinal incision into left upper quadrant. The tail of pancreas was identified after spleen was lifted. Then a total of 1 Â 10 6 viable Pan02 cells suspended in 20 mL of ice-cold Matrigel were injected into pancreatic parenchyma using an ice-cold 27-gauge needle and an ice-cold calibrated syringe. The spleen and pancreas were placed back into abdominal cavity, and a running two-layer silk suture closed the abdominal cavity. Postoperative status and wound healing were monitored every day for one week. All of the animal study protocols were duely approved by the Institutional Ethics Committee for Animal Care of Shanghai Laboratory Animal Center, Chinese Academy of Sciences.
Immunostaining of p32 in tissues
All of the human pancreatic cancer, paratumor pancreatic tissue, orthotopic mouse pancreatic cancer, and mouse normal tissues were immersed sequentially in 4% paraformaldehyde for 15 min, 10% sucrose for 1 h and 30% sucrose overnight immediately after they were resected. Then the tissues were imbedded in OCT compound, frozen at À20 C and sliced into 4-mm tissue sections. The following primary antibodies were used: rabbit anti-p32 (CST, USA), goat anti-EpCAM (Santa-Cruz, USA), and Cy2-conjugated donkey anti-rabbit and Cy3-conjugated donkey anti-goat (Jackson ImmunoResearch, USA) second antibodies were used to visualized the conjugated primary antibody under fluorescence microscopy. DAPI was used as counterstained.
p32 expression in total protein and membrane protein extractions from cell line and tissue
Cell lines were harvested and rinsed with PBS twice, subsequently lysed and centrifuged at 16000 g to obtain the total protein. Fresh tissues of tumor, pancreas, heart, liver, spleen, lung, and kidney obtained from C57BL/6 mice with orthotopic pancreatic cancer were homogenized and centrifuged at 16000 g to obtain total protein. The membrane protein of cell lines and tissue was extracted using the Transmembrane Protein Extraction Kit (Merck, Germany). Following the determination of the proteins concentrations with BCA protein assay kit, total protein and extracted membrane protein were fractionated by PAGE and transferred to polyvinylidene fluoride membranes. For p32 detection, membranes were probed with primary rabbit anti-p32 (1:1000 dilution) overnight at 4 C followed by horseradish peroxidaseeconjugated goat anti-rabbit IgG. Chemiluminescent detection was done with the enhanced chemiluminescence detection kit. 
Synthesis and characterization of the multifunctional

Synthesis of Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres
The uniform magnetite nanoparticles were synthesized according to the method reported previously [40] . 5 mL of the magnetite n-hexane dispersion (ca. 20 mg/mL) was diluted in a mixture of 10 mL of otcanol and 10 mL of trixton X-100 were dispersed in 50 mL of cyclohexane by ultrasonication for 10 min. Then, 0.5 mL of ammonium hydroxide solution (28 wt%) was added to form a stable inverse microemulsion solution. After that, TEOS (0.04 mL) was added under continuous mechanical stirring, and the reaction was allowed to proceed for 24 h to form a dispersion of silica-coated magnetite nanoparticles, i.e. Fe 3 O 4 @SiO 2 sample. Meanwhile, APTS (0.02 g) was dissolved in 5.0 mL of ethanol containing 0.01 g of FITC. After stirring for 12 h in dark, the resultant solution together with TEOS (0.02 mL) was added to the above Fe 3 O 4 @SiO 2 dispersion, and the reaction was allowed to proceed for another 12 h in dark. The product was purified and collected by magnetic separation, washed with ethanol three times and vacuum dried overnight at 30 C, thus FITC-embedded magnetic silica (Fe 3 O 4 @SiO 2 -FITC) nanospheres were obtained. To further grow a porous silica shell, Fe 3 O 4 @SiO 2 -FITC nanospheres were redispersed in a mixture solution containing CTAB (0.2 g), deionized water (40 mL) and n-hexane (3 mL) by ultrasonication. The resultant solution was mechanically stirred for 30 min, and then concentrated ammonia solution (0.4 mL, 28 wt %), and 0.20 mL of TEOS was added dropwise under continuous stirring. After stirring for 12 h at 30 C in dark, the product was collected by magnetic separation and washed repeatedly with ethanol. The obtained sample was refluxed in ethanol solution at 80 C for 12 h to remove CTAB template molecules. The resultant Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres was collected and washed with ethanol with the help of magnetic separation, and finally re-dispersed in 30 mL ethanol for further use. The solid content was about 0.6 wt%.
Immobilization of LyP-1 on Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres
To further attach functional LyP-1 peptides onto Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres, 0.02 mL of g-mercaptopropyl triethoxysilane (MPTS) was added in the ethanol dispersion of Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres (20 mL, 0.6 wt%). After reaction for 12 h, the nanospheres modified with -SH groups were purified by three times of separation using a magnet to remove the excess MPTS, and was finally redispersed into ethanol (40 mL) for further reaction with the maleimide-LyP-1 compound. Briefly, into the ethanol dispersion nanospheres, 2.0 mL of ethanol solution containing 0.01 g of Maleimide-LyP-1 peptide was added, and the reaction was allowed to proceed for further 6 h. The product was collected by centrifugation, washed with ethanol three times and finally vacuum dried at 30 C, and thus Fe 3 O 4 @SiO 2 -FITC@mSiO 2 eLyP-1 nanospheres were obtained.
Characterizations
Powder X-ray diffraction (XRD) patterns were recorded on a Bruker D8 Advanced X-ray diffractometer (Germany) with Nifiltered Cu Ka radiation (40 kV, 40 mA). Nitrogen sorption isotherms were measured at 77 K with a Micromeritics ASAP 2420 analyzer (USA). Before measurements, the samples were degassed in vacuum at 50 C for 4 h. The Brunauer-Emmett-Teller (BET) method was utilized to calculate the specific surface areas using adsorption data in a relative pressure range from 0.05 to 0.35. By using the Barrett-Joyner-Halenda (BJH) model, the pore volumes and pore size distributions were derived from the adsorption branches of isotherms, and the total pore volumes were estimated from the adsorbed amount at a relative pressure P/P0 of 0.992. Transmission electron microscopy (TEM) images were taken with a JEOL 2011 microscope (Japan) operated at 200 kV. Samples were first dispersed in ethanol and then collected using carbon-filmcovered copper grids for analysis. Scanning electronic microscopy (SEM) images were recorded on a Philips XL30 electron microscope (Netherlands) operating at 20 kV. A thin gold film was sprayed on the sample before measurements. Fluorescent microscopy observation was carried out by dropping the aqueous dispersion of Fe 3 O 4 @SiO 2 -FITC@mSiO 2 on a glass slide and images were taken on a confocal microscopy (LSM 410, Zeiss, Germany) using a 480 nm excitation with a band-pass 515e565 nm filter and a transmitted light detector. The C, H, N and S contents were measured on a Vario EL III elemental analyzer (Germany).
Cytotoxicity assay of the nanospheres
XTT assay was used to quantify the viability of the cells after treated with Fe 3 (5, 10, 20, 40, 80, 160 , 320 mg/mL). After incubation at 37 C with 5% CO2 for 24 h, 40 mL of XTT/PMS solution (Sigma-Aldrich, USA) at concentration of 1 and 0.05 g/L respectively, was added to each well. After further incubation for 4 h, the absorbance of each well was measured using a BioTek Synergy 2 ELISA reader (Bio-Tek, USA) at 570 nm. Mean and standard deviation for 6 parallel wells for each sample were reported.
Quantification of Fe 3 O 4 @SiO 2 -FITC@mSiO 2 eLyP-1 or Fe 3 O 4 @SiO 2 -FITC @mSiO 2 nanospheres bound with cell line by flow cytometry
Pan02 and MS1 were seeded in 6-well plates at a density of 1 Â 10 6 cells per well in 2 mL of completed culture medium. After overnight incubation to allow cells to adhere to dish, culture medium was replaced with fresh medium containing PBS buffer (as control), Fe 3 O 4 @SiO 2 -FITC@mSiO 2 eLyP-1 or Fe 3 O 4 @SiO 2 -FITC@m-SiO 2 at gradient concentration (5, 10, 20, 40, 80 mg/mL). After incubation for another 4 h, the culture medium was removed. Cells were washed with PBS 3 times, trypsinized, fixed with 2% paraformaldehyde, centrifuged and resuspended in 1 mL of PBS before flow cytometry analysis using a FACS Calibur flow cytometer (Becton Dickinson, USA). Three replicates were set at each concentration.
In vitro MR imaging of cell lines cultured with Fe 3 O 4 @SiO 2 -FITC@mSiO 2 eLyP-1 or Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres
Cell lines in 6-well plates cultured with gradient concentrations (5, 10, 20, 40 mg/mL) of Fe 3 O 4 @SiO 2 -FITC@mSiO 2 eLyP-1 or Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres were trypsinized, centrifuged according to procedure described in flow cytometry analysis. Cells were finally resuspended in 1% agarose for MR imaging. MR images were acquired on a 3 T Siemens Magnetom Trio (Shanghai key Lab of fMRI, Shanghai, China), using an eight-array loop coil (Siemens Medical Systems). For T2 -weighted MR imaging, the following parameters were adopted: FOV ¼ 120 mm Â 120 mm, matrix ¼ 128 Â 128, section thickness ¼ 2 mm, TE ¼ 13.8 ms, TR ¼ 4000 ms, number of averages ¼ 1.
2.5. Tissue distributions of Fe 3 O 4 @SiO 2 -FITC@mSiO 2 eLyP-1 or Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres after systemic delivery in C57BL/6 mice bearing orthotopic pancreatic cancer C57BL/6 mice with orthotopic pancreatic xenograft tumor were established as previously described. Three weeks later, mice were anesthetized by intraperitoneal injection of 1% phenobarbital sodium (70 mg/kg). Then Fe 3 O 4 @SiO 2 -FITC@mSiO 2 eLyP-1 or Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres dispersed in 0.2 mL of PBS (at Fe concentration 0.1 mM) were delivered into the tumor bearing C57BL/6 mice through tail vein. After 4 h, mice were euthanized, and the tumor, paratumor pancreas, liver, spleen, kidney, heart, lung were resected and subsequently fixed and sliced into 4-mm tissue sections as described above. Before observation under fluorescent microscope, all the tissues were immunostained with rabbit anti-p32 antibody and the nuclei were counterstained by DAPI.
In vivo MR imaging of orthotopic pancreatic tumor in C57BL/6 mice
Tumor bearing mice were anesthetized as described above. The same MRI system described above was used to perform the scan. 
Results and discussion
p32 expression in pancreatic cancer tissues and cell line
LyP-1, a cyclic nine amino acid peptide was initially found to bind to lymphatic vessels in MDA-MB-435 human breast cancer xenografts. Later on, it was confirmed to accumulate in xenograft breast cancer tissue after systemic delivery, while seldom detected in normal tissue [41, 42] . Recently, the p32 or gC1qR receptor, a protein primarily localized in the mitochondria [36, 37] , has been confirmed to be the target molecule for the LyP-1 peptide. Interestingly, in addition to over expression in tumors, it also showed aberrant cell surface expression of p32 in tumor lymphatics, tumor cells and a subset of myeloid cells [38] . All of these findings clearly indicate that LyP-1 is an ideal candidate molecule for cancer diagnostics and therapeutics [30e35]. However, to date, no systemic work has been done to study the feasibility of LyP-1 as active theranostics ligand in pancreatic cancer.
Firstly, the possible p32 protein expression in pancreatic cancer tissue was shown using immunostaining. The EpCAM was also labeled to differentiate the cancer cells from stromal cells. It is clearly indicated much more p32 expressions in mouse C57BL/6 orthotopic pancreatic cancer compared to those in paratumoral pancreas. Most of p32 expressing cells are epithelial derived as shown by the EpCAM double positive staining. A small portion of sole p32 expressing cells can be attributed to be the interstitial cells (Fig. 2a ). The similar difference between human pancreatic cancer and paratumoral pancreatic tissue is even more striking, which agrees well with the report by Rubinstein [43] .
The western blot results indicated that the p32 expressions in total protein were identical between the mouse pancreatic cancer cell line Pan02 and mouse endothelial cell line MS1, while the p32 content from membrane of Pan02 was higher than that in MS1. Similar to the previous report by Fogal et al. [38] , the p32 expression level in extracted membrane protein of tumor tissue was also higher than the counterparts in normal organ in tumor bearing C57BL/mice, while no significant difference of p32 expression was noticed in total protein between tumor tissue and normal tissues such as heart, liver, spleen, lung, pancreas and kidney (Fig. 2b) . To the best of our knowledge, this is the first time to elucidate the unique p32 protein expression in C57BL/6 derived pancreatic cancer cell line and its corresponding tumor tissues. These findings provide the solid basis of using LyP-1 as an affinity ligand in targeted theranostics in orthotopic pancreatic cancer in mouse C57BL/6.
Synthesis and characterization of LyP-1 immobilized multifunctional magnetic nanospheres
To design multifunctional nanospheres with uniform sizes, well-defined structure and integrated functions, ultrafine magnetite nanoparticles with superparamagnetic property were first synthesized through a solvothermal reaction [40] . The obtained magnetite nanoparticles have a uniform size of around 10 nm as estimated from transmission electron microscopy (TEM) image (Fig. S1 ). Then, magnetite nanoparticles were successively coated with silica and FITC-embedded silica through sol-gel reaction in an inverse microemulsion, and magnetic composite nanospheres with well-protected FITC were obtained and denoted as Fe 3 O 4 @SiO 2 -FITC. After that, the nanospheres were further coated with layer of mesoporous silica shells using cetyltrimethylammonium bromide (CTAB) as the porogen, the obtained multifunctional nanospheres, denoted as Fe 3 O 4 @SiO 2 -FITC@mSiO 2 , have a uniform diameter of 45 nm and well-defined core-shell structure (Fig. 3a) . From the magnified TEM image (Fig. 3a, inset) , it can be clearly seen that the dark magnetite core is surrounded by gray porous silica shell, and the mesopore size is about 2.0 nm in diameter as estimated from the image. Scanning electron microscopy (SEM) image shows that the multifunctional core-shell nanospheres are well dispersed and have a mean diameter of 45 nm, in good agreement with the TEM results (Fig. 3b) . The fluorescent microscopy image shows that the nanospheres can be well dispersed in an aqueous solution and show high luminescent intensity (Fig. S2) . The silica matrix can stably incorporate FITC molecules, preventing them from photo-and chemical bleaching [44] . X-ray diffraction (XRD) measurements reveal that the obtained multifunctional nanospheres exhibit diffraction patterns similar to those of the magnetite nanoparticles (Fig. S3) , except that the peaks intensity is slightly reduced due to the shielding effect of nonmagnetic silica shells. These results suggest that the crystalline structure of magnetite is well preserved during the whole coating process. The magnetic characterization using superconductive quantum interfacing device (SQUID) at 300 K indicates that both Fe 3 O 4 nanoparticles and Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres exhibit superparamagnetic behavior (Fig. 3c) with the latter having were further modified with g-mercaptopropyl triethoxysilane (MPTS) via surface grafting method, which endowed the nanospheres with rich eSH groups on surface [45] . Element analysis showed that the content of MTPS was 3.68 wt%. Taking the high surface area (318 m 2 /g) of the nanospheres into account, the grafting density of eSH group was calculated to be 2.93 Â 10 17 /m 2 . Such a high grafting density was attributed to the high surface area of the nanospheres, which was of great advantage to further conjugate with the terminal maleimide group of the maleimide-LyP-1 derivative. The successful conjugation of LyP-1 peptides was verified by Fourier transform infrared (FTIR) spectra (Fig. S5 ). After modification of Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres by MPTS, the typical absorption peak for eSH group can be seen at around 2570 cm À1 . However, this peak is relatively weak due to the low content of MPTS in the sample. After further modification with LyP-1, the characteristic absorption peaks for LyP-1 at 1660-1710 cm À1 were detected for Fe 3 O 4 @SiO 2 -FITC@mSiO 2 -LyP-1 nanospheres due to the amide groups eC(NH 2 )]O and eC(NH)]O from LyP-1. Moreover, Zeta potential of Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres was measured to be À10.7 mV. While the Fe 3 O 4 @SiO 2 -FITC@mSiO 2 -LyP-1 nanospheres have a Zeta potential of À14.9 mV due to the presence of enormous amino groups in the LyP-1 shell. Based on the element analysis on the Fe 3 O 4 @SiO 2 -FITC@mSiO 2 and Fe 3 O 4 @SiO 2 -FITC@mSiO 2 -LyP-1 samples, the content of LyP-1 grafted onto the nanospheres was about 12 wt%, accounting for a high grafting rate of LyP-1 of about 2.0 Â 10 17 /m 2 on the nanospheres. The hydrodynamic size of the Fe 3 O 4 @SiO 2 -FITC@m-SiO 2 -LyP-1 dispersed in water was measured by dynamic light scattering (DLS). The results showed that the hydrodynamic radius of Fe 3 O 4 @SiO 2 -FITC@mSiO 2 -LyP-1 was about 118 nm, larger than the value estimated from TEM image, mainly due to the presence of hydrated LyP-1 shell in the surface of the nanospheres. The T2weighted magnetic resonance images at 3T of the synthesized Fe 3 O 4 @SiO 2 -FITC@mSiO 2 -LyP-1 dispersed in water at different concentrations (0e4.71 mM) were shown in Fig. S6 . As the concentration increased, the signal intensity of the T2-weighted phantom image decreased obviously (Fig. S6a) , and the values of R2 (1/T2) increased linearly (Fig. S6b) , demonstrating that our multifunctional nanospheres can effectively shorten the T2 relaxation time and have a great promise for application as T2 weighted MRI contrast agent. The transverse relaxivity (r2) of Fe 3 O 4 @SiO 2 -FITC@mSiO 2 -LyP-1 was calculated to be 9.63 mM À1 s À1 from the plot in Fig. S6b . The above results clearly indicate that the obtained multifunctional Fe 3 O 4 @SiO 2 -FITC@mSiO 2 -LyP-1 nanospheres not only possess uniform size at sub-50 nm scale and well-defined structure of multi-components but also have highly integrated properties and highly modified surfaces, which is extremely useful for the following in vitro and in vivo study. Before applying the functional magnetic nanospheres for biomedical applications, it is essential to assess their cytotoxicity. The cytotoxicity of Fe 3 O 4 @-SiO 2 -FITC@mSiO 2 -LyP-1 and Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres were studied through XTT assay using mouse pancreatic cancer cell line (Pan02) and mouse endothelial cell lines (MS1). The results indicate that the cell viability does not have significant change after treatment with the two groups of samples in the concentration range of 0e320 mg/mL (Fig. 3d) , confirming a good biosafety of these nanomaterials.
Flow cytometry assay and in vitro MR imaging
Incorporation of FITC in silica shells of magnetic nanospheres makes it possible to quantitatively investigate functional nanoparticles bind to cells by flow cytometry in vitro [17, 46] . After incubation for 4 h, the mean fluorescent intensity of Pan02 cells increased sharply after culturing with Fe 3 O 4 @SiO 2 -FITC@mSiO 2 -LyP-1 nanospheres, even at a concentration as low as 5 mg/mL ( Fig. 4a ). It is mainly due to the high density of LyP-1 grafted on the porous silica shell, which could specifically recognize and bind to the Pan02 cell effectively. As the concentration increased, the fluorescent intensity increased slightly and reached a plateau at a concentration of 40 mg/mL. By contrast, the fluorescent intensity of Pan02 cells cultured with the non-target Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres was only about half of those cultured with LyP-1 conjugated nanospheres. The results confirmed that LyP-1 could specifically bind Pan02 cells even after immobilized on the multifunctional nanospheres surface. Few nanospheres were captured by MS1, yielding much lower fluorescent intensity, regardless of whether the nanospheres were linked with LyP-1 peptide or not, due to lack of expression of p32 on MS1.
As is well known, iron oxide nanoparticles typically yield MRI contrast with signal reduction due to the T2 relaxation time shortening effect, and the MRI intensity is mainly determined by the concentration of iron oxide nanoparticle [6,17,21,46e48] . Therefore, in this study, MRI was employed to study signal changes of Pan02 and MS1 cells after incubation with nanospheres of varied concentrations by T2 relaxometry measurement. With the increase of the concentration of Fe 3 O 4 @SiO 2 -FITC@mSiO 2 -LyP-1 nanospheres, the T2 weight MR signal of Pan02 dramatically became "darker", namely, indicating an increasing amount of magnetic nanospheres bound to Pan02 cells. By contrast, no obvious MRI contrast change was observed for Pan02 cells after co-cultured with (Fig. 4b) . These results provided additional evidence that LyP-1 anchored on the nanospheres could guide the recognition of p32 expressing Pan02 cells.
Tissue distributions of multifunctional nanospheres after systematic delivery in C57BL/6 mice bearing orthotopic pancreatic cancer
The stably trapped FITC in the magnetic nanospheres greatly facilitates to tract the functional nanoparticles in tissue sections under fluorescent microscopy. Magnetic nanospheres were injected through tail vein of C57BL/6 mice bearing orthotopic pancreatic tumor. After circulation for 4 h, mice were sacrificed and tissue sections of tumor and other main organs were made. Before observation under fluorescent microscopy, the possible p32 expressions in all the tissues were explored by immunostaining to illustrate the specific binding of LyP-1 peptide with p32. In the group of mice injected with Fe 3 O 4 @SiO 2 -FITC@mSiO 2 -LyP-1 nanospheres, the accumulation of FITC labeled nanospheres were noticed in tumor tissue. Though the nanospheres were not distributed evenly, their distributions highly overlapped with p32 protein. Almost no fluorescent nanospheres were detected in heart, lung or kidney, except that a few coarse fluorescent particles were found to retain in liver and spleen mainly due to the uptake of partly aggregated LyP-1 conjugated nanospheres by hepatic and spleen reticuloendothelial system. In C57BL/6 mice bearing orthotopic pancreatic cancer injected with Fe 3 O 4 @SiO 2 -FITC@m-SiO 2 nanospheres, no obvious fluorescent nanospheres accumulation was observed in tumor tissues due to lack of specific interaction of the highly dispersed nanospheres and tumor cells. Similarly, no fluorescent nanospheres were found in liver, spleen, heart, lung or kidney (Fig. 5) . The above tissue distribution analysis based on the combination of fluorescent labeling and immunostaining of p32 receptor further verified the active targeting of LyP-1 to its corresponding receptor p32, and it also demonstrated the versatility of our rationally designed superparamagnetic Fe 3 O 4 @-SiO 2 -FITC@mSiO 2 -LyP-1 nanospheres.
In vivo MR imaging
The superparamagnetic characteristics of our magnetic nanospheres make it possible to be administrated as MR imaging contrasts to detect pancreatic tumor lesions in vivo. By comparing the T2-weighted MR images at 3T of the tumor-bearing mice before and after administration of Fe 3 O 4 @SiO 2 -FITC@mSiO 2 -LyP-1 nanospheres, a gradual reduction of signal in tumor area was noticed after circulation for 1 h, and reached the lowest intensity at 4 h, suggesting selective accumulation of the magnetic nanospheres in the pancreatic cancer. The decreased signal maintained in the tumor area even after 24 h, which indicated the good stability of the magnetic nanoparticle, due to the protection of silica shells (Fig. 6) . By contrast, no apparent MRI signal change was observed in the tumors of mice receiving Fe 3 O 4 @SiO 2 -FITC@mSiO 2 nanospheres. The in-vivo experiments confirmed that ultrafine superparamagnetic Fe 3 O 4 @SiO 2 -FITC@mSiO 2 -LyP-1 nanospheres in our study were successfully demonstrated as effective MR contrasts due to their superparamagnetic property, and the immobilized LyP-1 could mediate their active targeting in tumor area, achieving MR imaging at molecular level.
As the results showed above that p32 expression in human pancreatic cancer was much higher than that of paratumoral pancreas (Fig. 2a ). It is expected that our designed multifunctional LyP-1 conjugated nanospheres hold a great promise for application in early human pancreatic cancer diagnosis.
Conclusions
In summary, for the first time, we systematically showed the aberrant membrane expression of p32 in mouse pancreatic cancer cell line Pan02 and its syngeneic orthotopic transplantation xenograft. The ligand of p32, LyP-1, was conjugated to FITC labeled magnetic mesoporous silica nanospheres for multi-model specific and precise detection of pancreatic cancer. The obtained multifunctional mesoporous nanospheres, Fe 3 O 4 @SiO 2 -FITC@mSiO 2 -LyP-1, possess uniform size of about 50 nm, well-protected magnetite core of 10 nm, stable fluorescent layer protected by silica, high grafting density of LyP-1 (2 Â 10 17 /m 2 ) and good biocompatibility. Flow cytometry and in vitro MR imaging verified the specific targeting of LyP-1 immobilized nanospheres to pancreatic cancer cells, causing a signal reduction of T2 relaxation.
In vivo experiments demonstrated specific accumulation of LyP-1 immobilized FITC labeled nanospheres in tumor tissue, yielding an excellent MR imaging of orthotopic pancreatic cancer xenograft. These results lay a solid foundation for our designed multifunctional LyP-1 immobilized nanospheres to be used in early diagnosis of pancreatic cancer. Furthermore, as the orthotopic pancreatic cancer was established in immunocompetent C57BL/6 mice, we believe that the LyP-1 immobilized magnetic mesoporous nanospheres also pave the road to target immunotherapy research in pancreatic cancer.
